Search

Displaying results 1031 - 1040 of 10000 in total
  1. Drug

    Nefazodone

    go.drugbank.com/drugs/DB01149
    ApprovedWithdrawn

    Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. … On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.

  2. Drug

    Tocofersolan

    go.drugbank.com/drugs/DB11635
    Approved

    It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop. … In addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS].

  3. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes. … [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production.

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  4. Drug

    Netilmicin

    go.drugbank.com/drugs/DB00955
    Approved

    Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. … The bactericidal effect of netilmiicin is not fully understood.

    Synonyms: 1-N-Ethylsisomicin
  5. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID). … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]

    Mixtures: NuDroxiPAK N-500Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  6. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

  7. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].

  8. Drug

    Fludarabine

    go.drugbank.com/drugs/DB01073
    ApprovedInvestigational

    It is commonly marketed under the brand name Fludara.

  9. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366].

    Categories: N-methyl-D-aspartate Receptor Antagonist
  10. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid